Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
The objective-response rate and the progression-free survival among patients with advanced melanoma who had not previously received treatment were significantly greater with niv...
Publications
1 shownFrequent Co-Authors
Researcher Info
- h-index
- 1
- Publications
- 1
- Citations
- 2,716
- Institution
- Bristol-Myers Squibb (United States)
External Links
Impact Metrics
h-index
1
h-index: Number of publications with at least h citations each.